Kensuke Kanaoka

Kensuke Kanaoka

Auto-generated profile, based on publicly available information

Kensuke Kanaoka

Department of Respiratory Medicine and Clinical Immunology, Graduate School of Medicine The University of Osaka Osaka Japan

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 January 2021 in Respiratory Medicine Case Reports
Verified
Journal Article
Open access
KKKensuke Kanaoka
Kensuke Kanaoka
SMSeigo Minami
Seigo Minami
SIShoichi Ihara
Shoichi Ihara
TTTsunehiro Tanaka
Tsunehiro Tanaka
HYHironao Yasuoka
Hironao Yasuoka
KKKiyoshi Komuta
Kiyoshi Komuta
Coronavirus disease 2019 (COVID-19) has been reported to induce persistent symptoms even after an acute phase. However, the pathophysiology and treatment of this condition have been unclear. We report two patients who recovered from COVID-19, but presented persistent respiratory symptoms. Their respiratory conditions deteriorated, and computed tomography showed remaining ground glass opacities and consolidations. The pathological findings of transbronchial lung biopsy corresponded to organizing pneumonia. We diagnosed them with secondary organizing pneumonia after COVID-19. Subsequently, we administered systemic corticosteroids. Their symptoms, oxygenations, radiologic findings, and pulmonary functions rapidly improved after the treatment of corticosteroids. The two cases showed that secondary organizing pneumonia may be a cause of persistent respiratory failure after COVID-19. In this condition, corticosteroids may be effective.

6 September 2023 in BMC Cancer
Verified
Journal Article
Open access
PDF file
KKKensuke Kanaoka
Kensuke Kanaoka
HSHiromitsu Sumikawa
Hiromitsu Sumikawa
SOShunsuke Oyamada
Shunsuke Oyamada
ATAkihiro Tamiya
Akihiro Tamiya
YIYuji Inagaki
Yuji Inagaki
KOKyoichi Okishio
Kyoichi Okishio
Background: Osteoblastic bone reaction (OBR) refers to an increase in bone density at the site of bone metastasis or the appearance of new sclerotic bone lesions after anticancer treatment. OBR can be misunderstood as disease progression. In this study, we aimed to investigate the prevalence and details of OBR and its association with clinical outcomes in patients with epidermal growth factor receptor (EGFR)-mutant non-small cell lung cancer (NSCLC) treated with osimertinib. Methods: This was a single-center, retrospective cohort study. We reviewed patients who were diagnosed with EGFR-mutant NSCLC with bone metastasis and received osimertinib as a first-line treatment between February 2018 and October 2022. The OBR was evaluated by comparing baseline computed tomography (CT) scans with the first CT scan after treatment initiation. Results: A total of 45 patients were included in this study. Thirty-seven patients (82%) developed OBR. OBR developed in 94% (n = 16) of patients with sclerotic bone lesions (n = 17) at baseline. Similarly, OBR developed in lytic and mixed bone lesions in 76% and 82% of patients with lytic and mixed lesions, respectively. Progression-free survival (PFS) did not differ significantly between patients with (OBR group) and without OBR (non-OBR group) (median PFS, 24 months vs. 17 months; hazard ratio (HR), 0.62; 95% CI, 0.24–1.6; p = 0.31). In univariate analysis, the OBR group showed a trend toward longer skeletal-related events-free survival (SRE-FS) than the non-OBR group (median SRE-FS, 26 months vs. 12 months; HR, 0.53; 95% CI, 0.21–1.33; p = 0.16). Multivariate analysis showed OBR was a significant independent predictor of SRE-FS (HR, 0.35; 95% CI, 0.13–0.92; p = 0.034). Conclusions: OBR developed in most patients with NSCLC and bone metastasis who received osimertinib treatment. The increased incidence of OBR in patients with EGFR-mutant NSCLC with bone metastasis treated with osimertinib should not be confused with disease progression, and treatment decisions should be made carefully.

13 October 2024 in Respiratory Investigation
Verified
Journal Article
Closed access
KKKensuke Kanaoka
Kensuke Kanaoka
TAToru Arai
Toru Arai
TTTakayuki Takimoto
Takayuki Takimoto
MMMitsuhiro Moda
Mitsuhiro Moda
RSRyota Shintani
Ryota Shintani
SSShigeki Shimizu
Shigeki Shimizu

15 April 2023 in Thoracic Cancer
Verified
Journal Article
Open access
KKKensuke Kanaoka
Kensuke Kanaoka
SFShoich Fukuda
Shoich Fukuda
YIYuji Inagaki
Yuji Inagaki
YTYoshihiko Taniguchi
Yoshihiko Taniguchi
KNKeiko Nakao
Keiko Nakao
KOKyoichi Okishio
Kyoichi Okishio
Vocal code paralysis (VCP) is a rare complication of stereotactic body radiation therapy (SBRT). In most previously reported cases of VCP after SBRT, VCP was left‐sided because of anatomic vulnerability. Here, we report a case of right‐sided VCP following SBRT for non–small‐cell lung cancer. The patient was an 81‐year‐old man who underwent SBRT for synchronous lung cancer of the right upper and inferior lobes. He subsequently developed radiation pneumonitis and received corticosteroids. Lung contraction persisted, and the mediastinum shifted to the right because of lung volume reduction. After corticosteroids discontinuation, the patient developed hoarseness and voice weakness. An endoscopic test showed right‐sided VCP. Imaging examinations did not reveal new lesions, including lung cancer recurrence. Therefore, we diagnosed the patient with SBRT‐associated VCP and speculated that the injury to the right vagal nerve and recurrent laryngeal nerve resulted from mechanical traction due to intense lung contraction, which might have induced VCP. We should be alert to VCP following SBRT, even if the target lesions are right‐sided.

2 June 2026 in Thoracic Cancer
Verified
Journal Article
Open access
KYKeijiro Yamauchi
Keijiro Yamauchi
KMKinnosuke Matsumoto
Kinnosuke Matsumoto
TSTakayuki Shiroyama
Takayuki Shiroyama
ATAkihiro Tamiya
Akihiro Tamiya
MTMotohiro Tamiya
Motohiro Tamiya
AKAtsushi Kumanogoh
Atsushi Kumanogoh
Introduction: Bevacizumab, an anti‐VEGF antibody, inhibits angiogenesis and modulates the tumor microenvironment. Because systemic inflammation is linked to VEGF activation and immune modulation, it may affect bevacizumab efficacy. However, this relationship remains unclear. We therefore evaluated whether systemic inflammation, assessed via the serum C‐reactive protein (CRP) level, modifies survival benefit when adding bevacizumab to chemoimmunotherapy in advanced non‐squamous non‐small cell lung cancer (NSCLC). Methods: We retrospectively analyzed patients with advanced non‐squamous NSCLC from 13 Japanese institutions receiving first‐line atezolizumab plus chemotherapy with or without bevacizumab between December 2018 and December 2022. The primary endpoint was overall survival (OS). The interaction between CRP level (< 1 mg/dL vs. ≥ 1 mg/dL) and bevacizumab treatment was evaluated, and sensitivity analyses were performed to confirm the robustness of our findings. Results: Among 193 eligible patients, 109 (56.5%) received bevacizumab. With a median follow‐up of 44.2 months, the median OS was 24.5 months in patients with low CRP and 17.3 months in those with high CRP (log‐rank test for trend, p = 0.04). Bevacizumab significantly improved OS in patients with high CRP (hazard ratio [HR] 0.63; 95% confidence interval, 0.40–0.99; p = 0.04), but not in those with low CRP (HR 1.22; p = 0.50). The interaction between CRP level and bevacizumab treatment was significant ( p = 0.033). Sensitivity analyses supported these results. Conclusions: Systemic inflammation, as assessed by CRP level, may modify the efficacy of bevacizumab in advanced non‐squamous NSCLC. These hypothesis‐generating findings warrant prospective validation to clarify the role of CRP in treatment stratification.